Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
The Growing Role of Monoclonal Antibodies in Relapsed/Refractory Follicular Lymp...
Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.
Tisagenlecleucel Leads to High CR Rate in Heavily Pretreated, R/R Follicular Lym...
Tisagenlecleucel induced a significant number of complete responses in patients with relapsed or refractory follicular lymphoma, meeting the primary end point of the phase 2 ELARA trial as of the interim analysis of the study.
Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.
ZUMA-5: high ORR and CR for R/R iNHL with axi-cel
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives an update on the ongoing Phase II ZUMA-5 trial (NCT03105336) of axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR)-T cell therapy, for patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma and marginal zone lymphoma (MZL).
Interim data from phase II Zuma-5 study (axicabtagene ciloleucel in FL and MZL) ...
Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR T-cell therapy, leads to a high rate of strong and sustained responses in adults with relapsed or refractory (resistant) follicular lymphoma, known as FL, or marginal zone lymphoma, called MZL, who received at least two prior therapy lines, according to interim data from a Phase 2 trial.